CBMS: FILO

Virus-Like Particle Trivalent Filovirus Vaccine process Development, Formulation, and Manufacturing Efforts

Purpose
The requirement for a vaccine to protect against filovirus exposure is described in the Department of Defense (DoD) Joint Requirements Oversight Council (JROC) approved Joint Medical Biological Warfare Agents Prophylaxes Initial Capabilities Document (ICD), dated September 14, 2004. The ICD calls for a medical prophylaxis that will provide broad spectrum protection against a range of biological warfare agents and a range of exposure routes. The Joint Vaccine Acquisition Program Joint Product Management Office (JVAP JPMO), a subordinate organization to Chemical Biological Medical Systems Joint Project Management Office (CBMS JPMO), is responsible for the development, production, and stockpiling of Food and Drug Administration (FDA)-licensed vaccine products to protect the Warfighter against Biological Warfare agents.

Register for Bidder's Library Solicitation Documentation
Registered Users Only FedBizOps Posting

Point of Contact
Nathan Jordan
508-233-6169
nathan.c.jordan.civ@mail.mil

/Team/FILO.aspx